Search clinical trials for: Defactinib

Total 31 results

Verastem, Inc.

Completed

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer

United States
Verastem, Inc.

Completed

A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects

Healthy Subjects
Memorial Sloan Kettering Cancer Center
Verastem, Inc.

Recruiting

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

Thyroid Cancer

United States
Verastem, Inc.

Terminated

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants

Malignant Pleural Mesothelioma

United States
Verastem, Inc.

Completed

Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies

Non Hematologic Cancers

Japan
University of Utah
Verastem, Inc.

Recruiting

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma (DETERMINE)

Melanoma

United States
University of Oklahoma
Verastem, Inc.

Recruiting

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (DURAFAK)

Cervical Cancer | Solid Tumor | Endometrioid Cancer | Mucinous Ovarian Cancer | High Grade Serous Ovarian Cancer

United States
Memorial Sloan Kettering Cancer Center
Verastem, Inc.

Recruiting

A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

Mesonephric Gynecologic Cancer

United States
Verastem, Inc.

Terminated

Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma (COMMAND)

Malignant Pleural Mesothelioma

United States, Belgium, United Kingdom, Sweden, Italy, Netherlands, France, Japan, Australia, Canada, New Zealand, Norway, Poland, South Africa, Spain
National Cancer Institute (NCI)

Active, not recruiting

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Institute of Cancer Research, United Kingdom
Verastem, Inc.

Active, not recruiting

Phase I Trial of Defactinib and VS-6766. (FRAME)

Pancreatic Cancer | NSCLC | Low Grade Serous Ovarian Cancer | Endometrioid Carcinoma

United Kingdom
Raphael Bueno, MD
Merck Sharp & Dohme LLC

Withdrawn

Pembrolizumab + Defactinib In Pleural Mesothelioma

Malignant Pleural Mesothelioma

United States
Verastem, Inc.

Completed

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer (RAMP202)

Non Small Cell Lung Cancer | KRAS Activating Mutation

United States, Spain, France, Germany, Italy
M.D. Anderson Cancer Center

Not yet recruiting

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
Verastem, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (RAMP 201)

Ovarian Cancer | Low Grade Ovarian Serous Adenocarcinoma

Spain, United States, Belgium, United Kingdom, France, Canada, Italy
NHS Greater Glasgow and Clyde
Merck Sharp & Dohme LLC; Cancer Research UK; University of Southampton; Queen's... and other collaborators

Unknown

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

Pancreatic Neoplasms | Mesothelioma | Carcinoma, Non-small-cell Lung

United Kingdom
Verastem, Inc.

Terminated

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

Epithelial Ovarian Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC; Verastem, Inc.

Recruiting

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

United States
Washington University School of Medicine
National Cancer Institute (NCI); Verastem, Inc.

Recruiting

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Pancreas Adenocarcinoma | Pancreas Cancer | Cancer of the Pancreas

United States
Verastem, Inc.

Completed

Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer

Ovarian Cancer

United States
Michael McHale
Verastem, Inc.; Nine Girls Ask

Recruiting

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Ovarian Cancer

United States
Clinical Hub for Interventional Research (CHOIR)
The University of New South Wales; Australian National University

Recruiting

Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (CELESTIAL-MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Australia
Verastem, Inc.
Amgen

Recruiting

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients (RAMP203)

Non Small Cell Lung Cancer | KRAS Activating Mutation

United States, United Kingdom, Netherlands, Belgium
Emory University
National Cancer Institute (NCI); Verastem, Inc.

Recruiting

Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

Glioblastoma | Recurrent Glioblastoma

United States
Verastem, Inc.

Recruiting

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (RAMP205)

Metastatic Cancer | Pancreas Cancer | Neoplasms Pancreatic | KRAS Activating Mutation | Malignant Neoplasm of Pancreas

United States
Washington University School of Medicine
Merck Sharp & Dohme LLC; The Foundation for Barnes-Jewish Hospital; Verastem,...

Completed

Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer

Pancreatic Cancer | Advanced Solid Tumors | Solid Tumors

United States
Verastem, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

Low Grade Serous Ovarian Cancer

United States, Australia
Boehringer Ingelheim

Completed

Telmisartan+Amlodipine Fixed Dose Combination in Hypertension

Hypertension

China
Thomas Jefferson University
Verastem, Inc.

Active, not recruiting

Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

United States
Amsterdam UMC, location VUmc
VitrOmics BV

Terminated

Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study (TSAP)

Advanced Solid Tumors | Metastasis | Inoperable

Netherlands
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam

Search clinical trials for: Defactinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations